Skip to Content


In the US, Daclizumab (daclizumab systemic) is a member of the drug class interleukin inhibitors and is used to treat Multiple Sclerosis and Organ Transplant - Rejection Prophylaxis.

US matches:



ATC (Anatomical Therapeutic Chemical Classification)


CAS registry number (Chemical Abstracts Service)


Chemical Formula


Molecular Weight


Therapeutic Category


Chemical Name

Immunoglobulin G 1 (human-mouse monoclonal clone 1H4 t-chain anti-human interleukin 2 receptor), disulfide wit human-mouse monoclonal clone 1H4 light chain, dimer

Foreign Names

  • Daclizumabum (Latin)
  • Daclizumab (German)
  • Daclizumab (French)
  • Daclizumab (Spanish)

Generic Names

  • Daclizumab (OS: USAN, BAN, DCF)
  • Ro 24-7375 (IS)

Brand Names

  • Zenapax
    Productos Roche, Chile; Roche, Brazil; Roche, China
  • Zenapzx
    Roche, Oman


BANBritish Approved Name
DCFDénomination Commune Française
ISInofficial Synonym
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name

Further information on drug naming conventions: International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.